Aarkstore Enterprise || Ureter Cancer – Pipeline Review, H2 2012

1. Ureter Cancer – Pipeline Review, H2 2012
Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Ureter Cancer – Pipeline Review, H2 2012
RSS link of Global Markets Direct
Summary
Global Markets Direct’s, Ureter Cancer - Pipeline Review, H2 2012, provides an
overview of the Ureter Cancer therapeutic pipeline. This report provides
information on the therapeutic development for Ureter Cancer, complete with latest
updates, and special features on late-stage and discontinued projects. It also reviews
key players involved in the therapeutic development for Ureter Cancer. Ureter
Cancer - Pipeline Review, H2 2012 is built using data and information sourced from
Global Markets Direct’s proprietary databases, Company/University websites, SEC
filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources, put together by Global Markets
Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Ureter Cancer.
- A review of the Ureter Cancer products under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.

2. Ureter Cancer – Pipeline Review, H2 2012
Table of contents:
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Ureter Cancer Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Ureter Cancer 6
Ureter Cancer Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Early Clinical Stage Products 10
Comparative Analysis 10
Ureter Cancer Therapeutics – Products under Development by Companies 11
Companies Involved in Ureter Cancer Therapeutics Development 12
ImClone Systems Incorporated 12
Altor BioScience Corporation 13
Assessment by Combination Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Drug Profiles 19
IMC-1121B + Docetaxel - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ALT-801 + Gemcitabine + Cisplatin - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Ureter Cancer Therapeutics – Discontinued Products 23
Ureter Cancer Therapeutics - Dormant Products 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25

3. Ureter Cancer – Pipeline Review, H2 2012
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2
2012&PubId=&pagenum=1
Hepatic (Liver) Tumor – Pipeline Review, H2 2012
Diffuse Large B-Cell Lymphoma – Pipeline Review, H2 2012
Ureter Cancer – Pipeline Review, H2 2012
Acute Lymphoblastic Lymphoma – Pipeline Review, H2 2012
Fallopian Tube Cancer – Pipeline Review, H2 2012
Low-Grade Astrocytoma – Pipeline Review, H2 2012
Endometrial Cancer – Pipeline Review, H2 2012

4. Ureter Cancer – Pipeline Review, H2 2012
Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2012
Stroke – Pipeline Review, H2 2012
Peritoneal Cancer – Pipeline Review, H2 2012
Search More Reports Related to This Category :
Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1
For More details Plz do contact :
Aarkstore Enterprise
Lavanya
Phone:08149852585
Email: enquiry@aarkstore.com